SAB BIOTHERAPEUTICS, INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
SAB BIOTHERAPEUTICS, INC. (SABS) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was -$12.14K, a 253.72% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $57.66K.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $0.00.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was $32.33K.
- SAB BIOTHERAPEUTICS, INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$26.31K.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | -$13.00K 10-Q · filed 2026-08-06 | $45.53K derived: sum of 3 quarters · filed 2026-08-06 | $45.53K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$12.14K 10-Q · filed 2026-05-12 | $45.53K derived: sum of 2 quarters · filed 2026-05-12 | $45.53K derived: sum of 3 quarters · filed 2026-05-12 | $28.53K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $57.66K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $57.66K derived: sum of 2 quarters · filed 2026-03-09 | $40.66K derived: sum of 3 quarters · filed 2026-08-06 | $32.33K 10-K · filed 2026-03-09 | ||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | -$17.00K derived: sum of 2 quarters · filed 2026-08-06 | -$25.33K 10-Q · filed 2025-11-14 | -$35.41K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$17.00K 10-Q · filed 2026-08-06 | -$17.19K 10-Q · filed 2025-08-07 | -$24.00K 10-Q · filed 2026-08-06 | -$24.12K 10-Q · filed 2025-08-07 | -$35.41K derived: sum of 3 quarters · filed 2026-08-06 | -$35.41K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $7.89K 10-Q · filed 2026-05-12 | -$18.41K derived: sum of 2 quarters · filed 2026-05-12 | -$18.41K derived: sum of 3 quarters · filed 2026-05-12 | -$10.77K derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$26.31K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$26.31K derived: sum of 2 quarters · filed 2026-03-09 | -$18.66K derived: sum of 3 quarters · filed 2026-03-09 | -$26.31K 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $7.64K derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $7.64K 10-Q · filed 2025-08-07 | $15.17K 10-Q · filed 2025-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |